<DOC>
	<DOC>NCT02615561</DOC>
	<brief_summary>1. Curing mild atopic dermatis in children with a commerical medical device (Bepanthen Itch Relief Cream). 2. Maintaining healthy skin by using a new cosmetic Bepanthen product or a commercially available cosmetic product</brief_summary>
	<brief_title>Curing Atopic Dermatits in Children With a Commerical Medical Device and Maintaining Healthy Skin by Using a New Cosmetic Product</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Pantothenic Acid</mesh_term>
	<criteria>Written parents' informed consent to have their child participate in the study and attend the study procedures and processes as outlined in the protocol Male or female babies/children aged between 1 month and 4 years Mild AD presenting a maximum SCORAD of 25 (at Screening and Baseline) Acute flareup phase Local SCORAD â‰¥ 5 on the target area (at Screening and Baseline) Skin type I IV according to Fitzpatrick Any other skin disease at the target area that would interfere the clinical assessment in the opinion of the investigator Known allergies to any of the ingredients of the IMPs Any other adjuvant therapy for AD (UV therapy, probiotics, homeopathy etc.) within 30 days before Baseline as well as during the entire study Any use of another topical emollient or other established treatment for AD during Phase 1 (cure phase) and Phase 2 (care phase) at the site of flares (AD lesions). Exception are usual hygienic products in the nappy area</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Atopic dermatitis</keyword>
	<keyword>Cosmetic products</keyword>
</DOC>